Addressing the risk for cirrhosis, liver failure and liver cancer among America’s veterans
Read More
Featuring in-depth discussions with physicians and administrators at some of the nation’s leading Federally Qualified Health Centers.
Global Healthcare Business and Technology Expert Leads Company Growth in Chronic Liver Disease Assessment
VA Broadens Contract with Echosens to Include FibroScan mini+ portable Technology, Expands Access to Screening and Early Detection
In this white paper, we explore the growing body of data that show how nonalcoholic fatty liver disease (NAFLD) is becoming recognized as a significant burden to patients, providers, and the overall healthcare system. One study concluded that the costs associated with the care for NAFLD were significantly higher than matched controls with similar metabolic profiles, even before the introduction of pharmacological treatments
Increased Education and Early Detection of Fatty Liver Disease
Highlights Value of Non-Invasive Screening for Fatty Liver Disease
FibroScan will be included in over 163 abstracts including 18 oral presentations that will evaluate utilization of the non-invasive FibroScan® tool across a variety of liver disease etiologies and practice settings
Given the shift to value-based medicine and the significant cost implications of NASH, the study explored which outcomes and quality measures KOLs would recommend for value-based contracting.
Pilot Study Underway Identifies Patients with Progressive Non-Alcoholic Fatty Liver Disease
